Study Finds Covidiens Mallinckrodt TaperGuard Endotracheal Tube Provides More Protection Against Microaspiration

April 7, 2010

Covidien, a leading global healthcare products company, announces that a new in vivo study concluded that the Mallinckrodt™ TaperGuard™ endotracheal tube provided significant protection from microaspiration and lung damage compared to the Mallinckrodt™ Hi-Lo endotracheal tube.

The findings were presented at the annual International Symposium on Intensive Care and Emergency Medicine (ISICEM) Meeting, in Brussels, Belgium.

The study, "Do Endotracheal Tubes Prevent Microaspiration?" was conducted by Peter Lichtenthal, MD, of the University of Arizona's Department of Anesthesiology; Ulf Borg, of Respiratory and Monitoring Solutions at Covidien; and Donald Maul, of Preclinical Research Services in Fort Collins, Colo.

The study compared the Hi-Lo tube, with a barrel-shaped cuff, and the new TaperGuard tube, which features a taper-shaped cuff. In the study, subjects were intubated prior to surgery with either the Hi-Lo or TaperGuard tubes. Blue dye was injected above the tubes, and afterward, the subjects’ trachea and lungs were evaluated for dye leak, bronchitis, ulceration and hemorrhagic pneumonia. The researchers found that the TaperGuard tube significantly outperformed the Hi-Lo tube in reducing dye leak and bronchitis, and also offered improved, potentially clinically significant, protection in the remaining categories.

By providing a more effective fluid seal, the TaperGuard tube with its taper-shaped cuff reduces the risk of microaspiration among intubated patients. Microaspiration refers to aspiration of fluid, secretions and other materials that have leaked past the endotracheal tube cuff and into the lungs – a common problem in intubation that may lead to pulmonary complications, including ventilator-associated pneumonia (VAP) and post-operative pneumonia.

VAP is the most common hospital-acquired infection and the leading cause of morbidity and mortality in the intensive care unit.(1) VAP is also associated with longer hospital stays and increased healthcare costs.(2)

“Postoperative pulmonary complications are common and costly, posing a serious risk for both patient and the healthcare facility; however, that risk is potentially preventable,” said Douglas Hansell, MD, MPH, chief medical officer and vice president of Respiratory and Monitoring Solutions. “The ability of the TaperGuard tube to reduce microaspiration of subglottic secretions can help achieve better patient outcomes as well as substantial cost-savings for healthcare facilities.”

References

1. National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1997, issued May 1997. A report from the NNIS System. Am J Infect Control. 1997;25(6):477-487.

2. Collard HR, Saint S. Prevention of ventilator-associated pneumonia. Agency for Healthcare Research and Quality. Rockville, Md. Available at: http://www.ahrq.gov/clinic/ptsafety/chap17a.htm.